Incyte's ruxolitinib scores its second approval in two days, this time in chronic graft-versus-host disease
A day after approving a topical formulation of Incyte’s cash cow ruxolitinib for atopic dermatitis, regulators are back with more good news for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
